MK-3814A
Total Payments
$79,382
Transactions
25
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $24,285 | 9 | 0 |
| 2017 | $55,097 | 16 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $77,920 | 22 | 98.2% |
| Consulting Fee | $1,463 | 3 | 1.8% |
Payments by Type
Research
$77,920
22 transactions
General
$1,463
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1b,II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies | Merck Sharp & Dohme Corporation | $77,920 | 0 |
Top Doctors Receiving Payments for MK-3814A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Grand Rapids, MI | $77,920 | 22 |
| , M.D | Diagnostic Radiology | Kendall Park, NJ | $1,463 | 3 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $79,382
Product Information
- Type Drug
- Total Payments $79,382
- Total Doctors 1
- Transactions 25
About MK-3814A
MK-3814A is a drug associated with $79,382 in payments to 1 healthcare providers, recorded across 25 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $24,285 was paid across 9 transactions to 0 doctors.
The most common payment nature for MK-3814A is "Unspecified" ($77,920, 98.2% of total).
MK-3814A is associated with 1 research study, including "A Phase 1b,II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies" ($77,920).